The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Executive Summary
Bayer's retreat from the global, primary-care stage into the mid-sized, regionally-focused specialist player arena was forced upon it by its own particular set of challenges. But other drug firms facing similar issues should take note: globalism may not be the best way forward in today's environment.